Advertisement


Reid Merryman, MD, on High-Risk Follicular Lymphoma: New Data on Epcoritamab, Rituximab, and Lenalidomide

2023 ASCO Annual Meeting

Advertisement

Reid Merryman, MD, of Dana-Farber Cancer Institute, discusses his findings on the regimen of epcoritamab plus rituximab and lenalidomide for patients with high-risk follicular lymphoma. Regardless of whether their disease progressed within 24 months of first-line chemoimmunotherapy, this regimen showed antitumor activity and a manageable safety profile in patients with relapsed or refractory disease. Epcoritamab, a subcutaneous T-cell–engaging bispecific antibody, may abrogate the negative effects of high-risk features (Abstract 7506).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
At ASCO this year I presented updated results from Epcoritamab plus R2 for patients with relapsed or refractory follicular lymphoma. Each of those three drugs, rituximab, lenalidomide, and epcoritamab, has different modes of action. It was hypothesized that lenalidomide with its immunomodulatory properties might enhance the activity of epcoritamab. In this study, patients received R2 over 12 cycles using standard dosing and two different doses of epcoritamab were tested, two different dose schedules. In arm 2A, patients received more frequent epcoritamab dosing, dosed weekly for the first three cycles, every two weeks for cycles four through seven, and every four weeks thereafter. Whereas an arm 2B, less frequent epcoritamab dosing was used every week for the first two cycles, and every four weeks thereafter. In total 111 patients were treated and they had received a median of one prior line of therapy. Notably, patients had many high risk features in this cohort. Approximately 60% of patients had Stage 4 disease. About 40% of patients had progression of disease within the first two years of chemoimmunotherapy treatment, so-called POD24 patients, and approximately 60% of patients had a high risk FLIPI score. The safety profile for this combination was similar to previous reports. The most common side effects included cytokine release syndrome, infections, and neutropenia. CRS was seen in about half of patients, but was primarily low grade with only 2% of patients having Grade 3 or higher CRS. CRS occurred over a predictable timeline. Almost all CRS occurred over the first two cycles, and most CRS occurred after the first full dose of epcoritamab, which was given on cycle one, day 15. Notably, CRS resolved in all patients and no patients discontinued epcoritamab based on cytokine release syndrome. Among all patients the overall response rate was 98%, and the complete metabolic response rate was 87%, both of which are very high for this disease setting. Notably, all patients did well, including those with high risk features like POD24, primary refractory disease or high FLIPI scores. With almost a median of one year of follow-up, the one-year progression-free survival was 78% and the one-year duration of complete response was 89% suggesting that these responses are durable, at least so far. Responses seem to be durable for all patient subgroups, including those with POD24. I think our data suggests that this combination leads to deep and so far quite durable responses with a manageable safety profile. Based on this encouraging data, there's an ongoing randomized Phase 3 trial comparing R2 to R2 plus epcoritamab among patients with relapsed or refractory follicular lymphoma. More broadly, I think this trial adds to a growing number of studies that suggest that CD3/CD20 bispecific antibodies are a very potent treatment for follicular lymphoma and will likely be an important part of our treatment for FL patients in the years to come.

Related Videos

Colorectal Cancer

Sebastian Stintzing, MD, on Colorectal Cancer: Influence of Liquid Biopsy in First-Line Combination Treatment

Sebastian Stintzing, MD, of the Charité Universitätsmedizin Berlin, discusses results from the phase III FIRE-4 study, which showed that liquid biopsy is clinically relevant in verifying mutational status in patients with metastatic colorectal cancer and is efficacious in first-line treatment of FOLFIRI and cetuximab for patients with RAS wild-type disease (Abstract 3507).

Prostate Cancer

Alicia K. Morgans, MD, MPH, and Praful Ravi, MRCP, MBBChir, on Localized Prostate Cancer: Prognostic Impact of PSA Nadir

Alicia K. Morgans, MD, MPH, and Praful Ravi, MRCP, MBBChir, both of Dana-Farber Cancer Institute, discuss an individual patient-data analysis of randomized trials from the ICECAP collaborative. A PSA nadir of ≥ 0.1 ng/mL within 6 months after radiotherapy completion was prognostic for prostate cancer–specific, metastasis-free, and overall survival in patients receiving radiotherapy plus androgen-deprivation therapy for localized prostate cancer. These findings may help identify patients for therapy de-escalation trials (Abstract 5002).

Prostate Cancer

Alicia K. Morgans, MD, MPH, and Karim Fizazi, MD, on Prostate Cancer: Phase III Results on Talazoparib Plus Enzalutamide as First-Line Treatment

Alicia K. Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Karim Fizazi, MD, of Institut Gustave Roussy, University of Paris-Saclay, discuss findings from the TALAPRO-2 study, which showed that talazoparib plus enzalutamide improved radiographic progression–free survival over standard-of-care enzalutamide as first-line treatment for patients with metastatic castration-resistant prostate cancer and HRR gene alterations. This regimen also delayed the time to deterioration in global health status and quality of life (Abstract 5004).

Lung Cancer
Genomics/Genetics

Narjust Florez, MD, and Ferdinandos Skoulidis, MD, PhD, on NSCLC: Findings on Sotorasib vs Docetaxel in the CodeBreaK 200 Trial

Narjust Florez, MD, of Dana-Farber Cancer Institute, and Ferdinandos Skoulidis, MD, PhD, of The University of Texas MD Anderson Cancer Center, discuss results of a biomarker subgroup analysis, showing that sotorasib demonstrated consistent clinical benefit vs docetaxel in all molecularly defined subgroups of patients with pretreated KRAS G12C–mutated advanced non–small cell lung cancer (NSCLC). Although no predictive biomarkers were confirmed, novel hypothesis-generating signals were observed (Abstract 9008).

Leukemia
COVID-19

Jennifer A. Woyach, MD, on New Findings on CLL, COVID-19, and Treatment With Obinutuzumab Plus Venetoclax

Jennifer A. Woyach, MD, of The Ohio State University Comprehensive Cancer Center, discusses results of a phase III study showing that progression-free survival with ibrutinib plus obinutuzumab plus venetoclax is not superior to ibrutinib plus obinutuzumab for treatment-naive older patients with chronic lymphocytic leukemia (CLL) in the setting of the COVID-19 pandemic. Long-term follow-up will determine whether there are advantages to obinutuzumab plus venetoclax, with special attention to measurable residual disease and therapy discontinuation (Abstract 7500).

Advertisement

Advertisement




Advertisement